PharmAlert.net

PharmAlert Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Gilenya: FDA warns about cases of progressive multifocal leukoencephalopathy in patients with multiple sclerosis


The FDA ( Food and Drug Administration ) warned that a case of definite progressive multifocal leukoencephalopathy ( PML ) and a case of probable PML have been reported in patients taking Gilenya ( Fingolimod ) for multiple sclerosis.
These are the first cases of progressive multifocal leukoencephalopathy reported in patients taking Gilenya who had not been previously treated with an immunosuppressant drug for multiple sclerosis or any other medical condition.
As a result, information about these recent cases is being added to the drug label.

Gilenya is an immunomodulator shown to benefit patients with relapsing forms of multiple sclerosis. This type of multiple sclerosis causes attacks or relapses, which are periods of time when symptoms get worse.
Immunomodulators alter the immune system to reduce inflammation.
Progressive multifocal leukoencephalopathy is a rare and serious brain infection caused by the John Cunningham ( JC ) virus. The JC virus is a common virus that is harmless in most people but can cause progressive multifocal leukoencephalopathy in some patients who have weakened immune systems, including those taking immunosuppressant drugs.

In an August 2013 Drug Safety Communication, FDA reported that a patient developed progressive multifocal leukoencephalopathy after taking Gilenya.
Progressive multifocal leukoencephalopathy could not be conclusively linked to Gilenya in this case because prior to Gilenya treatment the patient had been treated with an immunosuppressant drug that can cause progressive multifocal leukoencephalopathy and during Gilenya treatment the patient had received multiple courses of intravenous corticosteroids, which can weaken the immune system.

Recommendation

Patients taking Gilenya should contact their health care professionals right away if they experience symptoms such as new or worsening weakness; increased trouble using their arms or legs; or changes in thinking, eyesight, strength, or balance.
Patients should not stop taking Gilenya without first discussing it with their health care professionals. Health care professionals should stop Gilenya and perform a diagnostic evaluation if progressive multifocal leukoencephalopathy is suspected. ( Xagena )

Source: FDA, 2015

XagenaMedicine_2015



Indietro